uploads/2018/02/VRX-analysts-reco-1.png

Valeant Pharmaceuticals on the Street: Analyst Ratings This February

By

Updated

A company overview of VRX

Valeant Pharmaceuticals (VRX) is a specialty pharmaceutical company involved in the development, manufacture, and marketing of branded, generic, branded generic as well as over the counter products. The company is also into medical devices, including contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices.

Valeant’s products are marketed in more than a 100 countries.

Article continues below advertisement

VRX’s analyst ratings

Of the seven analysts covering Valeant Pharmaceuticals in February 2018, two analysts have given the stock a “buy” or higher rating. Three analysts have given it a “hold” rating, and two analysts have given the stock a “sell” rating. The mean rating for the stock is 2.86, with a target price of $19.96.

Notably, Valeant Pharmaceuticals makes up about 0.02% of the Vanguard FTSE All-World ex-US ETF’s (VEU) total portfolio holdings.

Peer ratings

Of the 29 analysts covering Gilead Sciences (GILD) in February 2018, 17 analysts have given the stock a “buy” or higher rating, and 12 analysts have given it a “hold” rating. The mean rating for the stock is 2.21, with a target price of $87.79.

Of the 12 analysts covering Horizon Pharmaceuticals (HZNP) in February 2018, 11 analysts have given the stock a “buy” or higher rating, and one analyst has given it a “hold” rating. The mean rating for the stock is 1.83, with a target price of $19.08.

Of the 23 analysts covering Jazz Pharmaceuticals (JAZZ) in February 2018, 18 analysts have given the stock a “buy” or higher rating, and five analysts have given it a “hold” rating. The mean rating for the stock is 1.96, with a target price of $181.

In the next part of the series, we’ll take a look at the recent divestments by Valeant Pharmaceuticals.

Advertisement

More From Market Realist